Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. Goodin DS, et al. Among authors: wicklein em. Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15. Mult Scler. 2019. PMID: 29761737
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. Kappos L, et al. Among authors: wicklein em. Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10. Neurology. 2016. PMID: 27511182 Free PMC article. Clinical Trial.
Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group. Fitzgerald KC, et al. Among authors: wicklein em. Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965. Ann Neurol. 2017. PMID: 28556498 Free PMC article. Clinical Trial.
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups. Buck D, et al. Among authors: wicklein em. Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9. Mult Scler. 2019. PMID: 29521573 Clinical Trial.
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.
Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE. Bendfeldt K, et al. Among authors: wicklein em. Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9. Brain Imaging Behav. 2019. PMID: 30155789 Free PMC article.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL. Manuel Escobar J, et al. Among authors: wicklein em. Mult Scler. 2022 Jul;28(8):1277-1285. doi: 10.1177/13524585211061861. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994579 Free PMC article.
22 results